Misoprostol for non-alcoholic steatohepatitis: a randomised control trial
Introduction The management of non-alcoholic steatohepatitis (NASH) is an unmet clinical need. Misoprostol, a structural analogue of naturally occurring prostaglandin E1, has been reported to decrease proinflammatory cytokine production and may have a potential role in treating NASH. We aimed to eva...
| Main Authors: | , , , , , |
|---|---|
| 格式: | Article |
| 語言: | English |
| 出版: |
BMJ Publishing Group
2024-07-01
|
| 叢編: | BMJ Open Gastroenterology |
| 在線閱讀: | https://bmjopengastro.bmj.com/content/11/1/e001342.full |